## (56) References Cited 

Author Unknown, "From Antinutrient to Phytonutrient: phytic acid gains respect." HighBeam Research, Environmental Nutrition, Apr. 1, 2004, 2 printed pages. URL: http://www.highbeam.com/doc/ lGl-116341390.htrnl/print (accessed Nov. 4, 2011). 

Bobo et al., "Convection-enhanced delivery of macromolecules in the brain", PNAS 91:2076-2080, 1994. 

Boman et al., "Optimization of the retention properties of vincristine in liposomal system", Biochimica et Biophysica Acta, 1152:253-258 (1993). 

CAS Registry Record for 23214-92-8 (doxorubicin), entered STN Nov. 16, 1984. 

CAS Registry Record for 97682-44-5 (irinotecan), entered STN Aug. 18, 1985. 

Chou et al., "Effect of Composition on the Stability of Liposomal Irinotecan Prepared by a pH Gradient Method", J Bioscience and Bioengineering, 95(4):405-408, 2003. 

Colbern et al., "Encapsulation of the Topoisomerase I Inhibitor GL147211C in Pegylated (STEALTH) Liposomes: Pharrnacokinet› ics and Antitumor Activity in HT29 Colon Tumor Xenografts", Clin. Cancer Research 4:3077-3082, 1998. 

Dickinson et al., "Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging", J Neurosurg 108:989-998, 2008. 

Dickinson et al., "Canine spontaneous glioma: A translational model system for convection-enhanced delivery", Neuro-Oncology 10:1093, 1-13, 2010. 

Drummond et al., "Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy", Cancer Res 66(6):3271-3277, 2006. 

Emerson et al., "Antitumor Efficacy, Pharrnacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formula› tion of Lurtotecan", Clinical Cancer Research 6:2903 2912,2000. 

Grahn et al., "Non-PEGylated liposomes for convection› enhanced ... experience", J Neurooncol 95: 185-197, 2009. 

Haran et al., "Transmembrane ammonium sulfate gradients in lipsomes produce efficient and stable entrapment of amphipathic weak bases", Biochimica et Biophysica Acta, 1151-201-215, 1993 Hattori et al., "Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors", J of Controlled Release 136:30-37, 2009. 

Hong et al. "Anti-HER2 Immunoliposomes for Targeted Drug Delivery, Annals of the New York Academy of Sciences." vol. 886, pp. 293-296. Dec. 1999. 

Katsu et al., "Ion-Selective Electrode for Transmembrane pH Dif› ference Measurements", Anal. Chem. 73:1849-1854, 2001. 

Kirpotin et al., "Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in Vitro", Biochemist 36:66-75, 1997. 

Ko et al., "A Multinational Phase II Study of PEP02 (MM-398), Liposome Irinotecan, for Patients with Gemcitabine-refractory Metastatic Pancreatic Cancer," Suppl. Abstract 4069. (2011). 

Krauze et al., Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposornal doxorubicin ( doxil) in rodent intracranial brain tumor xenografts, Neuro-Oncology, pp. 393-403, Oct. 2007. 

Lee et al. "Novel Chondroitin Sulfate binding Cationic Liposomes Loaded with Cisplatin Efficiently Suppress the Local Growth and Liver Metastasis of Tumor Cells in Vivo," Cancer Research 62, Aug. 1, 2002, 4282-4288. 

Liu et al., "A Versatile Prodrug Approach for Liposomal Core› Loading of Water-Insoluble Camptothecin Anticancer Drugs", J Am. Chem. Soc. 124:7650-7651, 2002. 

Maddison et al. "Small Animal Clinical Pharmacology." 2002. p. 474. 

Mamot et al., "Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery", J Neuro-Oncology 68:1-9, 2004. 

## OTHER PUBLICATIONS 

Maurer-Spurej et al., "Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients", Biochemica at Biophysica Acta 1416: 1-10, 1999. 

Mayer et al., Cancer Research 49:5922-5930, 1989. 

Messerer et al., "Liposomal Irinotecan: Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer", Clinical Cancer Research 10:6638-6649 2004. 

Miles et al. "Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer," The Oncologist, ?(suppl 6), 2002, pp. 13-19. 

Morrison et al., "Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics", Am. J Physiol. Regulatory Integrative Comp. Physiol. 277:1218-1229 1999. 

Morrison et al., High-flow Microinfusion: Tissue Penetration and Pharmacodynamics, Am. J Physiol., 266:R292-R305,1994. 

Nentwich, PF. "Intravenous Therapy." 1990. p. 310. 

Neve et al., "Biological Effects of Anti-ErbB2 Single Chain Anti› bodies Selected for Internalizing Function", Biochemical and Bio› physical Research Communications, 280:274-279 (2001). 

Nielsen et al., "Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis", Biochimica et Biophysica Acta, 1591: 109-118 (2002). Noble et al., "Novel Nanoliposomal CPT-11 Infused by Convection› Enhanced Delivery in Intracranial Tumors: Pharmacology and Effi› cacy", Cancer Res., 66(5):2801-2806, 2006. 

Ochi et al., "Crystalline Salts of Sucrose Octasulfate", Pharmaceu› tical Society of Japan 28:638-641, 1980. 

PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEPO2 (MM-398), Nanoliposomal Irinotecan, Press Release May 9, 2011. 

Pharmaengine, www.pharmaengine.com/pep02.htrnl Webpage titled "PEP02". Aug. 4, 2011. 

Poul et al., "Selection of Tumor-Specific Internalizing Human Antibodies from Phage Libraries", J Mo!. Biol., 301:1149-1161 (2000). 

Ramsay et al., "A Novel liposomal irinotecan formulation with significant to improve drug retention", European J of Pharmaceutics and Biopharmaceutics 68:607-617, 2008. 

Sadzuka et al. "Effect of Liposomalization on the Antitumor Activ› ity, Side-Effects, and Tissue Distribution ofCPT-11," Cancer Letters 127 (1998) 99-106. 

Saito et al., "Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model", Neuro-Oncology, pp. 205-214 2006. 

Saito et al., "Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging", Cancer Research 64:2572-2579 2004. 

Saito et al., Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brans: Implications for local drug delivery, J Neuroscience Methods 154:225-232, 2006. 

Shimada et al. "Irinotecan Plus Low-Dose Cisplatin for Alpha Fetoprotein-Producing Gastric Carcinoma with Multiple Liver Metastases: Report of Two Cases," Surg Today (2002) 32:1075 1080. 

Tardi et al., Liposomal Encapsulation ofTopotecan Enhances Anti› cancer Efficacy in Murine and Human Xeno raft Models, Cancer Research 60:3389-3393, 2000. 

Werbel et al., "Basically Substituted Ellipticine Analogues as Poten› tial Antitumor Agents", J Med. Chem. 29:1321-1322, 1986. 

Yamashita et al., "Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xeno rafts" Neuro-Oncology 8:1-9 2006. 

Yeh et al. "Structural Basis for Activation of Fibroblast Growth Factor Signaling by Sucrose Octasulfate," Molecular and Cellular Biology, vol. 22 No. 20, Oct. 2002, pp. 7184-7192. 

Zhu et al., Cancer Chemotherapy & Pharmacology, 39:138-142 1996. 

